



ABN 53 075 582 740

ASX ANNOUNCEMENT
14 October 2014

BNC105 DATA IN INTERNATIONAL PEER-REVIEWED CANCER JOURNAL

- *In animal models BNC105 combined with leading cancer drugs had prolonged anti-tumour effects*
- *Animals treated with existing drugs survived longer when combined with BNC105*
- *Partnering sought to move to new clinical trials*

Bionomics Limited (ASX:BNO, ADR:BMICY) advises that a research paper describing the utility of combining BNC105 with FDA approved anti-cancer targeted therapies has been accepted in the peer reviewed scientific journal ***Cancer Biology & Therapy***.

The data show that BNC105 treatment selectively induces a low oxygen state in tumours (hypoxia). During this state of hypoxia tumours attempt to survive by increasing expression of a number of growth factors that stimulate the formation of new blood vessels and new protein synthesis.

The report describes that these growth factors may be inhibited through concurrent treatment using BNC105 with the marketed anti-cancer drugs Avastin (Roche; US\$6.75 billion 2013 worldwide sales¹), Votrient (GSK, US\$517 million 2013 worldwide sales¹) or Afinitor (Novartis, US\$1.3 billion 2013 worldwide sales¹).

A pre-publication copy of the manuscript can be obtained from the journal by putting the following in your web browser: <https://www.landesbioscience.com/journals/cbt/article/956605/?nocache=2078656014>

Combination of BNC105 with each of these drugs caused prolonged anti-tumour effects resulting in greater inhibition of renal and breast solid tumour growth in preclinical models. Tumour-bearing animals survived longer when BNC105 was combined with the approved drugs compared to treating animals with each of the approved drugs alone.

"These discoveries provide the scientific rationale for clinical trials combining BNC105 with Avastin, Votient and Afinitor," said Dr Deborah Rathjen, Bionomics' CEO and Managing Director.

"Bionomics is actively exploring partnering opportunities to advance further clinical trials combining BNC105 with these targeted agents," said Dr Rathjen.

Avastin, Votrient and Afinitor are used to treat a number of cancer types, including renal cancer.

Bionomics last month reported data at the European Society for Medical Oncology (ESMO) congress arising from DisruptOR-1, a phase II clinical trial investigating the potential benefit of the BNC105+Afinitor combination treatment in patients with renal cancer. The trial data indicated that a subpopulation of patients exhibiting a 4 biomarker profile, experience improved therapeutic benefit with the combination compared to Afinitor alone, with 60% in Progression Free Survival (PFS) at 6 months. 57% of patients evaluated exhibited the biomarker profile correlating to PFS.

¹ 2013 sales figures according to Medtrack.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.